Showing 5581-5590 of 5956 results for "".
- ReNeuron Announces Presentation of Updated Efficacy and Safety Data from Retinitis Pigmentosa Studyhttps://modernod.com/news/reneuron-announces-presentation-of-updated-efficacy-and-safety-data-from-retinitis-pigmentosa-study/2476502/ReNeuron Group announced updated positive preliminary results in the company’s ongoing phase 1/2a clinical trial of its human retinal progenitor cell (hRPC) therapy candidate in retinitis pigmentosa (RP). All three subjects in the first cohort of the phase 2a part of the trial have demonstr
- Zeiss Launches First Dual-Speed Swept-Source OCT/OCTA at ARVOhttps://modernod.com/news/zeiss-launches-first-dual-speed-swept-source-oct-octa-at-arvo/2476503/Zeiss launched the PLEX Elite 2.0, the first dual-speed swept-source OCT/OCTA that will scan at 200kHz, in addition to 100kHz, providing doctors a more detailed view into the retina. Varying speeds can be applied to different disease states in the eye and expand re
- Presbia Abandons Flexivue Microlens, Lays Off All But 3https://modernod.com/news/presbia-abandons-flexivue-microlens-lays-off-all-but-3/2476501/Presbia said it spiked its Flexivue microlens development program in the face of FDA headwinds, laying off all but three of its employees as it seeks investors to bail it out, according to a Mass Device report. Earlier this month, the Irvine, Calif.-based company
- First Clinical Program Initiated Using Nanoparticles to Treat Retinitis Pigmentosahttps://modernod.com/news/first-clinical-program-initiated-using-nanoparticles-to-treat-retinitis-pigmentosa/2476490/2Ctech announced the initiation of the first-known clinical program to demonstrate the effectiveness and safety of Quantum Dots (QDs) to achieve photovoltaic stimulation of the neural retina for preservation or enhancement of vision in patients with retinal degenerative diseases and, in particula
- Optos Wins 2019 Queen’s Award for Enterprise Innovationhttps://modernod.com/news/optos-wins-2019-queens-award-for-enterprise-innovation/2476489/UK-based Optos has been recognized for its innovation with a 2019 Queen’s Award for Enterprise. Optos, which has sold more than 16,000 of its ultra-widefield imaging devices to eyecare professionals across the world, won the coveted accolade for the design of its
- Ivantis Announces Publication of Comparative MIGS Clinical Trial Resultshttps://modernod.com/news/ivantis-announces-publication-of-comparative-migs-clinical-trial-results/2476486/Ivantis, developer of the Hydrus Microstent, announced that the 12-month results of the COMPARE study for minimally invasive glaucoma surgery (MIGS) were accepted into the journal Ophthalmology, according to a company news release. COMPARE is the first prospective, multicenter, ra
- GenSight Biologics Reports Positive Follow-Up Results of Phase 3 Trial in LHONhttps://modernod.com/news/gensight-biologics-reports-positive-follow-up-results-of-phase-3-trial-in-lhon/2476475/GenSight Biologics announced results from the second scheduled readout, at week 72, of the RESCUE phase 3 clinical trial evaluating the safety and efficacy of a single intravitreal injection of GS010 (rAAV2/2-ND4) in 39 subjects whose visual loss due to 11778-ND4 Leber Hereditar
- Ophthotech Changes Name to Iveric bio as it Transitions to Gene Therapy Companyhttps://modernod.com/news/ophthotech-changes-name-to-iveric-bio-as-it-transitions-to-gene-therapy-company/2476473/Ophthotech announced that as part of its transition strategy to focus on discovering and developing novel gene therapy solutions to treat orphan inherited retinal diseases (IRDs) with unmet medical needs, the company
- Visioneering Technologies Creates Educational Series for Eye Care Practitionershttps://modernod.com/news/visioneering-technologies-creates-educational-series-for-eye-care-practitioners/2476471/Visioneering Technologies, maker of the NaturalVue Multifocal 1 Day contact lenses, announced the creation of a new educational series for eye care practitioners featuring some of the world’s leading researchers and clinicians, according to a company news release. The first installment of
- Proxy Advisory Firms Back Allergan in Battle with Dissident Shareholder Appaloosahttps://modernod.com/news/proxy-advisory-firms-back-allergan-in-battle-with-dissident-shareholder-appaloosa/2476472/Allergan said Monday that proxy advisory firms Institutional Shareholder Services (ISS) and Glass Lewis have recommended that shareholders vote for all of the board’s proposals at its annual meeting on May 1, and against hedge fund Appaloosa’s proposal calling for the immediate separa